MYOK - Why MyoKardia Shares Rose 62.8% in May
Shares of MyoKardia (NASDAQ: MYOK) climbed 62.8% in May, according to data provided by S&P Global Market Intelligence, after the company said its investigational heart drug met primary and secondary endpoints in a phase 3 clinical trial.
Image source: Getty Images.
Mavacamten is a treatment for obstructive hypertrophic cardiomyopathy (HCM), a chronic and progressive disease of the heart that results in reduced pumping capacity. In the phase 3 trial, the primary endpoint was a functional analysis that measured the drug's performance relative to placebo on symptoms and cardiac function. The secondary endpoints involved measures of shortness of breath, post-exercise left ventricular outflow, and characteristics associated with heart failure. Mavacamten resulted in statistically significant improvement across the board, and the drug was also well tolerated by patients.